NCT07294170ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis

N/A

A Prospective Longitudinal Study in Adults With Multifocal Motor Neuropathy

Multifocal Motor Neuropathy

N/A

Clinical Trials (1)

NCT05988073A Prospective Longitudinal Study in Adults With Multifocal Motor Neuropathy

N/A

efgartigimod

Generalized Myasthenia Gravis

N/A

Clinical Trials (1)

NCT04777734Efgartigimod Expanded Access for Generalized Myasthenia Gravis

N/A

Efgartigimod

Myasthenia Gravis

N/A

Clinical Trials (1)

NCT06299748A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding.

N/A

A Natural History Study in Participants With Congenital Myasthenic Syndromes (CMS) Due to Mutations

Congenital Myasthenic Syndrome

N/A

Clinical Trials (1)

NCT06078553A Natural History Study in Participants With Congenital Myasthenic Syndromes (CMS) Due to Mutations in DOK7, MUSK, AGRN, or LRP4

N/A

Efgartigimod PH20 SC

Chronic Inflammatory Demyelinating Polyradiculoneuropathy

N/A

Clinical Trials (1)

NCT07264426Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study

N/A

ITP Registry and Accompanying Biospecimen Collection

Immune Thrombocytopenia

N/A

Clinical Trials (1)

NCT05152238ITP Registry and Accompanying Biospecimen Collection

N/A

efgartigimod

Myasthenia Gravis

N/A

Clinical Trials (1)

NCT06298565A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa

N/A

ARGX-113

Bioavailability Study

Phase 1

Clinical Trials (1)

NCT03334084A Study to Compare the PK, PD and Safety and Tolerability of a SC With an IV Formulation of ARGX-113 in Healthy Male Subjects

Phase 1

ARGX-213

Healthy Volunteers

Phase 1

Clinical Trials (1)

NCT06968338A Study to Assess the Safety of ARGX-213 in Healthy Volunteers

Phase 1

Cusatuzumab

Leukemia, Myeloid, Acute

Phase 1

ARGX-111

Cancer

Phase 1

Clinical Trials (1)

NCT02055066A Phase 1b Study of ARGX-111 in Patients With Advanced Cancer.

Phase 1

efgartigimod IV

Healthy Volunteers

Phase 1

Clinical Trials (1)

NCT04564066A Phase 1 Study to Compare the Safety and Effect of Efgartigimod as an Intravenous Infusion With the Effect of Efgartigimod as a Subcutaneous Injection in Healthy Volunteers

Phase 1

ARGX-113

Healthy Volunteers

Phase 1

Clinical Trials (1)

NCT03457649IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers

Phase 1

Cusatuzumab

Leukemia, Myeloid, Acute

Phase 1

ARGX-119

Healthy Volunteers

Phase 1

Clinical Trials (1)

NCT05670704A Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single and Multiple Ascending Doses of ARGX-119 in Healthy Participants

Phase 1

ARGX-124

Healthy Volunteers

Phase 1

Clinical Trials (1)

NCT07377396A Study to Assess the Safety of ARGX-124 in Healthy Volunteers

Phase 1

ARGX-117

Healthy Volunteers

Phase 1

Clinical Trials (1)

NCT04532125SAD and MAD Study With IV and SC Doses of ARGX-117

Phase 1

ARGX-109

Healthy Volunteer

Phase 1

Clinical Trials (1)

NCT06799416A Study to Assess the Safety of ARGX-109 in Healthy Volunteers

Phase 1

ARGX-110

Cancer

Phase 1

Clinical Trials (1)

NCT02759250A Study of ARGX-110 in Patients With Nasopharyngeal Carcinoma (NPC)

Phase 1

ARGX-113 with rHuPH20

Healthy Volunteers

Phase 1

Clinical Trials (1)

NCT04073589Efgartigimod Co-administered Subcutaneously With rHuPH20 in Healthy Subjects

Phase 1

ARGX-119

Congenital Myasthenic Syndrome

Phase 1

Clinical Trials (1)

NCT06436742A Phase 1b Study to Investigate Safety and Tolerability of ARGX-119 in Adult Participants With DOK7-Congenital Myasthenic Syndromes (CMS)

Phase 1

efgartigimod PH20 SC as a prefilled syringe presentation

Bioequivalence

Phase 1

Clinical Trials (1)

NCT05817435A Phase 1 Bioequivalence Study of Efgartigimod PH20 SC Administered Via a Prefilled Syringe Versus a Vial+Syringe Presentation in Healthy Adults

Phase 1

Efgartigimod IV

Renal Impairment

Phase 1

Clinical Trials (1)

NCT05927415A Study to Test How Kidney Problems Influence the Blood Concentrations of Efgartigimod

Phase 1

Efgartigimod

Healthy Volunteers

Phase 1

Clinical Trials (1)

NCT05163834Immune Response to PNEUMOVAX 23 in Healthy Adults Receiving Efgartigimod IV

Phase 1

Efgartigimod

Epidermolysis Bullosa (EB)

Phase 1/2

Clinical Trials (1)

NCT07011589Targeting Collagen VII Antibodies in Bullous Diseases Using Efgartigimod IV (VYVGART)

Phase 1/2

ARGX-110

Leukemia, Myeloid, Acute

Phase 1/2

ARGX-110

Neoplasms

Phase 1/2

efgartigimod IV

Lupus Nephritis

Phase 2

Clinical Trials (1)

NCT05810948A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients With Lupus Nephritis (ZL-1103-013)

Phase 2

Efgartigimod Alfa-Fcab

Guillain-Barre Syndrome

Phase 2

Clinical Trials (1)

NCT05701189Evaluating Efgartigimod in Patients With Guillain-Barré Syndrome

Phase 2

Empasiprubart IV

Dermatomyositis

Phase 2

Clinical Trials (1)

NCT06284954A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis

Phase 2

ARGX-113

Myasthenia Gravis

Phase 2

Clinical Trials (1)

NCT02965573A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness

Phase 2

Azacitidine

Leukemia, Myeloid, Acute

Phase 2

ARGX-117

Delayed Graft Function

Phase 2

Clinical Trials (1)

NCT05907096ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft Function

Phase 2

ARGX-119 IV

Spinal Muscular Atrophy (SMA)

Phase 2

Clinical Trials (1)

NCT07287982A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy

Phase 2

ARGX-117

Multifocal Motor Neuropathy (MMN)

Phase 2

Clinical Trials (1)

NCT05405361A Clinical Trial to Investigate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults With Multifocal Motor Neuropathy

Phase 2

ARGX-117

Multifocal Motor Neuropathy

Phase 2

Clinical Trials (1)

NCT05225675A Clinical Trial to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of 2 Dose Regimens of ARGX-117 in Adults with Multifocal Motor Neuropathy

Phase 2

ARGX-113

Primary Immune Thrombocytopenia

Phase 2

Clinical Trials (1)

NCT03102593A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With ITP

Phase 2

Efgartigimod IV

AChR-Ab Seropositive Generalized Myasthenia Gravis

Phase 2

Clinical Trials (1)

NCT07284420ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod

Phase 2

Efgartigimod

Primary Sjögren's Syndrome

Phase 2

Clinical Trials (1)

NCT05817669A Study of the Safety and Effectiveness of Efgartigimod in Patients With Primary Sjögren's Syndrome (pSS)

Phase 2

Efgartigimod

Primary Sjögren's Syndrome

Phase 2

Clinical Trials (1)

NCT06203457Open-Label Extension Study to Evaluate the Safety of Efgartigimod in Adult Patients With Primary Sjögren's Syndrome

Phase 2

Azacitidine

Myelodysplastic Syndromes

Phase 2

Efgartigimod

Post-COVID Postural Orthostatic Tachycardia Syndrome Postural Orthostatic Tachycardia Syndrome

Phase 2

Clinical Trials (1)

NCT05918978Open Label Extension of Efgartigimod in Adults With Post-COVID-19 POTS

Phase 2

efgartigimod IV

Membranous Nephropathy

Phase 2

Clinical Trials (1)

NCT05810961A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients with Primary Membranous Nephropathy (ZL-1103-014)

Phase 2

ARGX-113

Pemphigus Vulgaris

Phase 2

Clinical Trials (1)

NCT03334058A Study to Evaluate the Safety, PD, PK and Efficacy of ARGX-113 in Patients With Pemphigus

Phase 2

Efgartigimod PH20 SC

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Phase 2

Clinical Trials (1)

NCT04280718A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)

Phase 2

Efgartigimod Alfa

Optic Neuritis

Phase 2

Clinical Trials (1)

NCT06453694Efgartigimod for the Treatment of Acute Optic Neuritis

Phase 2

Efgartigimod

Postural Orthostatic Tachycardia Syndrome

Phase 2

Clinical Trials (1)

NCT05633407Efficacy and Safety Study of Efgartigimod in Adults With Post-COVID-19 POTS

Phase 2

Efgartigimod PH20 SC - prefilled syringe

Antibody-mediated Rejection

Phase 2

Clinical Trials (1)

NCT06503731A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR)

Phase 2

efgartigimod PH20 SC in stage B

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Phase 2

Clinical Trials (1)

NCT04281472A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)

Phase 2

Open Jobs (56)

Interview Prep Quick Facts

Founded: 2008

Portfolio: 2 approved products, 80 clinical trials

Top TAs: Neurology, Hematology, Immunology

H-1B (2023): 1 approval

Open Roles: 56 active jobs

Portfolio Health

Growth1 (50%)

Peak1 (50%)

2 total products

Therapeutic Area Focus

30 pipeline

9 pipeline

1 marketed1 pipeline

1 marketed1 pipeline

2 pipeline

2 pipeline

2 pipeline

1 pipeline

Marketed

Pipeline

Hiring Trend

Actively Hiring

Open Roles

+21

Added

-5

Filled/Removed

Based on last 4 crawl cycles

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

argenx

Products & Portfolio (2)

Pipeline & Clinical Trials

Open Jobs (56)

Senior Manager, Scientific Communications

Associate Director, Market Access & Policy, Quebec

Security Awareness and Education Lead

Scientist Discovery

Scientist, Integrated Discovery Biology

Medical Safety Lead

Director of Corporate Strategy

Safety Scientist

Manager, US Medical Review

Scientist Computational Structural Biology

Tax Manager

Associate Director, Market Access & Policy, Ontario

Director Patient Support Programs (PSPs) Excellence

Senior Medical Writer

Associate Director, Medical Writing

Toxicologist late stage clinical development and established Assets

Medical Science Liaison, (Recife, Brazil)

Nurse Case Manager (Bilingual in Spanish required)

Regional Account Director, Northwest

Research Internship for Bachelors AY 2026-2027

Sr. Manager, Immunology Insights -Medical Insights Digital & Analytics Strategy

Managed Markets/Gross to Net Finance Director

Senior Medical Director Indication Lead

Biostatistics Director - Indication Lead

Associate Director, Global Ethics & Compliance Guidance & Training

Hiring Trend

Visa Sponsorship